Tuesday, September 3, 2013

Fate Therapeutics Approaches IPO, Sets IPO Range

Fate Therapeutics, the developer of stem cell technology which started in Seattle, is getting set for its IPO, saying in a regulatory filing this morning that it hopes to sell 4,000,000 shares of its common stock at between $14.00 and $16.00 per share. The biotech company, which is backed by ARCH Venture Partners, Polaris Partners, Venrock, and OVP Venture Partners, says it is looking to trade on the NASDAQ as FATE. Fate Theraputics now lists is headquarters as San Diego, California.